DR-037 Precision Cancer Therapy: Profiting from Tumor Specific Defects and Synthetic Lethality in the DNA Damage Tolerance Network

Tumor-specific defect in the DNA repair offer great potential for DNA damage based chemo/radio therapy. Present data implicate that this therapeutic intervention strategy has not been explored sufficiently. To provide optimal therapy with less side effects, there is an unmet need tot take further advantage of cancer-specific defect within the molecular network that controls DNA repair. This project will reveal the novel therapeutic opportunities for patients with tumor-specific DNA repair defects. The mission, optimize tumor intervention strategies to achieve higher cue rates with less side effects by developing optimised pesonalised medicine.

Heinz Jacobs NKI/AvL the Netherlands